Compare TMC & ABCL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TMC | ABCL |
|---|---|---|
| Founded | 2011 | 2012 |
| Country | Canada | Canada |
| Employees | N/A | N/A |
| Industry | Metal Mining | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.6B |
| IPO Year | 2020 | 2020 |
| Metric | TMC | ABCL |
|---|---|---|
| Price | $4.48 | $10.31 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 5 |
| Target Price | ★ $8.85 | $8.40 |
| AVG Volume (30 Days) | 4.1M | ★ 6.7M |
| Earning Date | 05-12-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 232.00 | 10.91 |
| EPS | ★ 0.05 | N/A |
| Revenue | N/A | ★ $75,128,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $21.85 |
| P/E Ratio | $91.00 | ★ N/A |
| Revenue Growth | N/A | ★ 160.56 |
| 52 Week Low | $3.40 | $2.75 |
| 52 Week High | $11.35 | $10.29 |
| Indicator | TMC | ABCL |
|---|---|---|
| Relative Strength Index (RSI) | 58.36 | 80.10 |
| Support Level | $4.24 | $3.38 |
| Resistance Level | $4.89 | N/A |
| Average True Range (ATR) | 0.24 | 0.65 |
| MACD | 0.14 | 0.51 |
| Stochastic Oscillator | 80.52 | 98.96 |
TMC The Metals Co Inc is a deep seabed minerals developer focused on the collection, processing and refining of polymetallic nodules found on the seafloor in international waters of the Clarion Clipperton Zone (CCZ), approximately 1,500 miles (or 2,400 kilometers) south-west of San Diego, California. The company operates as a single operating and reportable segment, namely exploration of seafloor polymetallic nodules, which includes the development of a metallurgical process to treat such seafloor polymetallic nodules.
AbCellera Biologics Inc is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody medicines for indications with high unmet medical need. It has built a platform for advancing antibody drug programs that the company believes provides it with a competitive advantage in addressing challenging, high-value targets such as complex transmembrane proteins and novel modalities, including multispecifics and antibody-drug conjugates. Organisation's pipeline includes two drug candidates in clinical development, two development candidates in Investigational New Drug (IND/Clinical Trial Application (CTA)-enabling activities, and more than 20 active discovery programs across multiple modalities and indications.